← Back to Clinical Trials
Recruiting NCT07365033

NCT07365033 Eccentric Exercise With Blood Flow Restriction vs Resistance Training for Lateral Epicondylitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07365033
Status Recruiting
Phase
Sponsor Nimra Rafiq
Condition Lateral Epicondylitis
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-01-30
Primary Completion 2026-03-30

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
interventional group Acontrol group b

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-01-30 with a primary completion date of 2026-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to compare the effectiveness of eccentric training combined with blood flow restriction (ECC+BFR) versus heavy slow resistance (HSR) training in patients with chronic lateral epicondylitis. The study will recruit 40 participants (accounting for 10% attrition), aged 25-45 years, from Sakina Memorial Hospital Sheikhupura and University of Lahore Teaching Hospital using convenience sampling. Participants will be randomly allocated into two groups: an interventional group receiving ECC+BFR and a control group undergoing HSR training. Both interventions will be administered three times per week for 8 weeks under professional supervision. Outcome measures including pain intensity (NPRS), patient-specific functional performance (PSFS), muscle strength, and hypertrophy will be assessed at baseline, 4 weeks, and 8 weeks. Data will be analyzed using SPSS, with appropriate parametric or non-parametric tests applied after checking data normality. Ethical approval will be obtained, informed consent will be secured, and participant confidentiality will be strictly maintained.

Eligibility Criteria

Inclusion Criteria: Patient aged between 25 and 45 years. Both male and female participants with unilateral symptoms only. Clinically diagnosed unilateral lateral epicondylitis (LE), confirmed by positive Cozen's and Mills' tests. Symptom duration exceeding 12 months, indicating chronic LE. Exclusion Criteria: Previous history of surgery or injection therapy for LE within the past 6 months. Coexisting conditions (e.g., rheumatoid arthritis, cervical radiculopathy, significant tendon tears). Contraindications to BFR (e.g., DVT, vascular disease, uncontrolled hypertension, clotting disorders). Use of anticoagulants or long-term pain medications. Pregnant or psychological person.

Contact & Investigator

Central Contact

Nimra Rafiq, MS MSK

✉ 701747512@student.uol.edu.pk

📞 0333 4170217

Principal Investigator

Nimra Rafiq, MS MSK

PRINCIPAL INVESTIGATOR

The University of Lahore, Lahore

Frequently Asked Questions

Who can join the NCT07365033 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 45 Years, studying Lateral Epicondylitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07365033 currently recruiting?

Yes, NCT07365033 is actively recruiting participants. Contact the research team at 701747512@student.uol.edu.pk for enrollment information.

Where is the NCT07365033 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07365033 clinical trial?

NCT07365033 is sponsored by Nimra Rafiq. The principal investigator is Nimra Rafiq, MS MSK at The University of Lahore, Lahore. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology